source
- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s e…Endpoints · 20d ago↗ source
- Updated: AstraZeneca sinks on unexpected heart drug trial failureAstraZeneca’s shares dropped in early trading Thursday after a heart disease treatment it is developing with Ionis Pharmaceuticals surprisingly failed in a late-stage trial. The companies had aimed…Endpoints · 20d ago↗ source
- Prime Medicine wins spat with Beam Therapeutics over AATD candidatePrime Medicine is headed for the clinic after winning a dispute with Beam Therapeutics, another gene editing biotech with roots in the same lab. Arbitrators determined that a 2019 contract between…